Unrelated-donor marrow transplantation is a potential option for transplant candidates lacking a compatible related donor. The T-cell Depletion Study compared the 3-year disease-free survival for patients receiving T-celldepleted (TCD) donor marrow (n ¼ 203) vs unmanipulated donor marrow with methotrexate and cyclosporine (M/C) (n ¼ 207). Hospital costs during index admission were documented with billing data, while hospital costs during subsequent 6-month follow-up were estimated from case report forms. Patients with index admission billing were included in the analysis (TCD ¼ 119, M/C ¼ 127). Total hospital length of stay (LOS) was similar across groups, with medians 47.0 days for TCD and 52.0 days for M/C (P ¼ 0.72). Total hospital costs were comparable, $145 115 vs $141 981 (P ¼ 0.63) for TCD and M/C, respectively. However, controlling for site and patient characteristics, TCD was associated with a 12.1% reduction in LOS for the index admission (95% CI À19.4%, À4.3%). Independent of treatment, HLA matching (6/6) was associated with an 8.6% (95% CI À17.4%, þ 1.2%) reduction in the index admission LOS, while cost was lower by 15.8% (95% CI À26.7%, À3.3%). Treatment costs were similar for TCD and M/C study groups. Savings on reduced cost for treating acute graft-versus-host disease were likely offset by increase in serious infections in the TCD arm.
Unrelated-donor (URD) marrow transplantation represents a potentially curative option for individuals who are candidates for an allogeneic transplant, but who do not have a compatible related donor. Graft-versus-host disease (GVHD) is a significant limiting factor in URD transplantation; not only does GVHD contribute to the morbidity and mortality of allogeneic transplantation, but also the management of patients with GVHD may add significant costs in the care of these recipients. 1, 2 If the severity of GVHD can be reduced or prevented, it may be possible to have an impact on both the costs and outcomes of URD transplants. However, this treatment modality is expensive and resource-intensive due to the complexity of the technology and the severity of the illnesses encountered by the transplant recipients. Patients must be prepared for an unrelated transplant and then require supportive care following transplant.
In 1993, the National Heart, Lung and Blood Institute proposed a study to determine the impact of T-cell depletion (TCD) on the 3-year disease-free survival (DFS) in recipients of URD marrow. Secondary clinical end points included overall survival, primary and secondary graft failure, acute and chronic GVHD, relapse, incidence of complications including infection, secondary malignancies and lymphoproliferative disease. In all, 15 centers participated in the trial, representing one of the first large multi-center, randomized clinical trials in the field of marrow transplantation. Between March 1995 and October 2000, consenting eligible patients were randomized to the use of in vitro methods of T-cell depletion of the donor marrow or the use of unmanipulated donor marrow to determine which strategy was better for the primary end point of 3-year DFS. The primary results of this trial are published elsewhere and briefly described below. 3 With a mean 4.7 years follow-up from the date of randomization, 3-year DFS was not statistically different between the TCD and methotrexate/cyclosporine (M/C) arm. For patients with acute leukemia, incidence of relapse and probability of DFS were similar between the two treatment arms. While survival in patients with CML was similar between arms, incidence of relapse was higher and DFS was lower in recipients of TCD.
Although the proportion of patients experiencing infection, time to first infection and types of infections were similar, severity (particularly CMV infections) was greater in TCD recipients. TCD was effective in decreasing the risk and severity of acute GVHD regardless of HLA match. Incidence of chronic GVHD at 2 years, however, was similar between the two treatment arms. Using the Bearman toxicity scale, incidence and severity of mucositis, hepatic, pulmonary, renal and CNS toxicities was greater among recipients of M/C.
The TCD trial had several substudies, an important one of which was an economic analysis. The rationale for doing this as part of the TCD trial was based on published criteria recommending inclusion of economic analysis in a clinical trial when: (1) a technology is utilized where sizeable resources are at stake; (2) the objectives of the various parties may be at variance (eg, insurers, investigators); (3) the alternatives are very different; (4) there is enough time to collect and analyze the results before the use of the technology becomes inevitable. 4, 5 Given the growing concern over health-care costs, it is important to assess the impact of the clinical and survival end points on the costs associated with the treatment. A primary hypothesis of the study was that T-cell depletion would decrease the incidence and severity of GVHD; this in turn could reduce the frequency or intensity of hospitalization, leading to a decrease in costs. Primary objectives of the economic analysis as established in planning for the TCD Trial were: (1) to compare resource utilization between the recipients of TCD bone marrow and recipients of non-TCD bone marrow; (2) to extrapolate the cost differences between patients receiving depleted and undepleted marrow from resource utilization data; and (3) to determine the incremental cost-effectiveness for TCD bone marrow.
Methods
All patients on the main protocol were eligible to be enrolled in the economic analysis. Prior to enrollment on the main protocol, all patients had to meet the protocoldefined eligibility criteria and sign the Institutional Review Board (IRB) approved informed consent documents that included consent to obtain hospital billing information for the economic component of the clinical trial.
The economic analysis encompassed two time segments: (1) the index hospital admission and (2) the 6-month follow-up period immediately following the index admission. Costs were measured from the hospital perspective and do not include physician professional fees or outpatient visits. All costs were adjusted to baseline year 2001 by means of the Hospital Producer Price Index published by the U.S. Bureau of Labor Statistics. 6 
Cost of index admission
Study sites were requested to obtain the Health Care Financing Administration (HCFA) Form UB-92 hospital summary discharge bill for each patient enrolled in the study. Billed charges were converted to costs using hospital-specific and year-specific Medicare cost-to-charge ratios.
Cost for follow-up hospital admission
Study sites were required to document hospital admissions during the 6-month follow-up period using a case report form (CRF) that recorded dates of admission and discharge, reason for admission and discharge status. However, collection of UB-92 billing forms was not requested because most of the admissions were expected to occur at hospitals not involved in the trial. Data from the CRF provided a basis for developing a file of similar admissions recorded in the Healthcare Cost and Utilization Project (HCUP) national hospital discharge database. 7 Using the HCUP files for 1995-2000, statistical models were developed to estimate the cost of admission as a function of diagnoses (the patient's underlying form of leukemia and the specific reason for admission), patient age and gender, length of stay (LOS), discharge status and year of admission. Charge was converted to cost using the national average Medicare cost-to-charge ratio.
Analysis
LOS and cost of the index admission, the 6-month followup period and the combined index admission plus followup period were compared using unadjusted descriptive statistics. Tests of the hypothesis of no difference across treatment groups were performed using t-tests, w 2 tests, and the Wilcoxon signed rank test. Effect of T-cell depletion on LOS and cost of the index admission, and the combined index and follow-up period were evaluated using multivariate regression with log transformation of the dependent variable to adjust for right-skewed data.
Results

Clinical study findings
The T-Cell Depletion Study was conducted at 15 sites, with the first patient enrolled in March 1995 and the last patient enrolled in October 2000 and completing 6-month followup for the last evaluable patient on 30 April 2001. Characteristics of the study population are shown in Table 1 . Of the 396 evaluable patients, 194 received TCD marrow and cyclosporine A (TCD), while 204 received M/C immunosuppression. Males comprised 55% of the study population. In all, 23% of patients were less than 18 years old, while 42% were more than 35 years old.
Study centers differed substantially in terms of numbers of patients enrolled. Three large centers enrolled 56.1% (222/396) of study subjects, while nine centers enrolling 10 or more patients accounted for 93.9% (372/396) of enrollment. Treatment patterns across these nine centers were compared by examining the use of selected relatively costly resources such as hyperalimentation, intravenous antibiotic therapy and ventilator days during the index hospital admission (Table 2) . While no formal statistical tests were performed, utilization of most of these resources, expressed as the number of units per 100 patient days, appeared comparable.
Economic study patient subset
Cost for the index admission was determined from the HCFA UB-92 summary discharge bill. Billing records were obtained for 62% (246/396) of patients eligible for analysis. The economic analysis as reported here is based on the subset of patients with billing records for the index admission (N ¼ 246). In a few cases, the index admission actually consisted of two or three sequential admissions separated by periods of a few days; LOS and charges were aggregated to create a single index admission bill for each patient. Comparison of characteristics for patients with and without index admission billing records is shown in Table 3 . No statistically significant differences were observed in age, gender, proportion of patients with diagnosis of CML, or treatment arm. However, index admission LOS was somewhat longer for the group without billing data (median 42 vs 36 days, Po0.01). Figure 1 illustrates the relative magnitude of components of treatment costs for the full study cohort based on the billed charges by hospital revenue center as reported on the UB-92 summary bills. Charges for room and board, including admissions to intensive care units, and pharmacy charges accounted for nearly two-thirds of total charges as observed in other economic analyses of stem cell transplantation published in Kline et al's study (1998). 2, 8 LOS and cost of the index hospital admission LOS and cost of the index admission for the subset of patients with billing data are shown in Table 4 . Both LOS and cost of admission appeared somewhat lower for the TCD group relative to the M/C group. However, LOS was not statistically different (P ¼ 0.55) with median 34.0 days for the TCD group vs 39.0 in the M/C group. Similarly, no statistical difference (P ¼ 0.18) was observed in the median cost for the index admission: $102 583 for the TCD group vs $115 413 in the M/C group.
LOS and cost of follow-up hospital admission
Patients were actively followed during the 6 months subsequent to discharge from the index hospital admission.
Figures for LOS and cost of admission for the six-month follow-up period (Table 4) are based on the economic study subset of patients with UB-92 s who survived the index admission: 62.2% (74/119) of the TCD group and 57.5% (73/127) of the M/C group. These data may reflect multiple admissions since patients in the TCD group were hospitalized an average of 3.7 times, while the conventional Table 1 Characteristics of the study population a Data based on sites enrolling X10 patients; sites enrolling o10 patients excluded.
Economic analysis of unrelated allogeneic BMT G de Lissovoy et al patients were admitted 3.5 times. LOS was not statistically different (P ¼ 0.31), with medians of 17.5 and 16.0 days for the TCD and M/C groups, respectively. A cost for each follow-up admission was imputed as previously described. Median follow-up hospital cost was $46 143 in the TCD group and $26 888 for the M/C group (P ¼ 0.36).
LOS and cost of admission for the combined index and follow-up periods
Combined LOS and costs for hospital admissions during the index treatment and 6-month follow-up period are also shown in Table 4 . Median LOS (eg, total hospital days) was similar across groups, 47.0 vs 52.0 days (P ¼ 0.72) for the TCD and M/C groups, respectively. The total cost for hospital admissions was also comparable: $145 115 for the TCD group vs $141 981 for the M/C group (P ¼ 0.63).
Effect of TCD on hospital LOS and costs
Determinants of LOS and cost for the index admission and the combined index admission and follow-up period admissions were explored using multivariate regression for the subset of patients with index admission billing records. The regression models controlled for treatment Figure 1 Relative value of resources used during the index admission. Table 5 . Regression parameters have been transformed into the percentage change in either LOS or cost as a function of the specified categorical variable. TCD was associated with a 12.1% reduction in LOS for the index admission (95% CI À19.4%, À4.3%), with a 5.3% reduction in cost of the index admission (95% CI À15.8%, 6.4%). When considering the combined index admission and follow-up periods, TCD was associated with a negligible 3.2% (95% CI À13.4%, þ 8.3%) decrease in total hospital days and 2.8% decrease in cost. Independent of treatment assignment, HLA matching was associated with an 8.6% (95% CI À17.4%, þ 1.2%) reduction in the index admission LOS, while cost was decreased by 15.8% (95% CI À26.7%, À3.3%). Over the combined index and follow-up period, LOS for patients with a 6 of 6 HLA match was decreased by only 2.2% (95% CI À10.0, þ 17.4%), while cost declined by 10.0% (95% CI À23.1, þ 5.3%).
Survival vs cost
Cost of treatment could be associated with duration of survival, such that patients surviving longer incur higher costs. In that case, a relative survival advantage for one of the study treatment groups could result in higher costs. To explore the relationship between cost and survival, the mean cost of treatment was calculated for subgroups categorized by duration of survival (Figure 2) . Costs for the two treatment groups were quite similar within survival duration categories. However, the relationship of cost vs survival appeared to follow a 'U-shape' pattern, where average costs increased with duration of survival up to the 121-150 day period and then began to decrease. This finding was substantiated in a linear regression that modeled cost as a parabolic (quadratic) function of survival duration (not shown).
Impact of GVHD on hospital costs
Patients in the TCD group were less likely to contract severe cases of acute GVHD than those in the M/C group. By day 100 post-transplant, 64.8% of the TCD patients had experienced grades 0ÀI acute GVHD compared with 41.4% in the M/C group. By contrast, 30.4% of patients in the M/C group experienced grades IIIÀIV acute GHVD compared with 16.2% among TCD patients. Cost of the 6-month treatment episode by highest severity level of GVHD is depicted in Figure 3 for each of the two treatment groups. Average costs rose progressively with increasing level of GVHD severity. However, costs within severity levels were similar across treatment groups. Severe levels of acute GVHD added a substantial amount to the cost of treatment. Relative to a patient who did not experience acute GVHD, cost in the first 6 months posttransplant, adjusted for treatment group and HLA matching, was increased by $60 419 for grade III acute GVHD and by $76 070 for grade IV acute GVHD (Po0.05). Table 5 Determinants of length of stay and cost for the index admission and for the combined index admission plus 6 month follow-up period Economic analysis of unrelated allogeneic BMT G de Lissovoy et al
Cost-effectiveness
Cost-effectiveness analysis measures the incremental cost and benefit of an intervention relative to a comparator. Cost-effectiveness for TCD relative to unmodified donor marrow in the TCD Study is calculated as:
The preferred metric for benefit is the quality-adjusted life-year (QALY), which reflects the period of survival weighted by patient preference for the health states experienced over that period. 9 The TCD Study included assessment of health-related quality of life at baseline and over the course of follow-up. However, no differences in quality of life that could be extrapolated to preference weights were observed by 1 year post-transplant. 10 An alternative measure of benefit is incremental survival. No difference in 3-year survival was recorded in the TCD Study. In situations where there is no difference in costs and no difference in benefits, cost-effectiveness analysis is not informative.
Discussion
The TCD trial is the largest multi-center, randomized, prospective trial in URD marrow transplant, with 3-year DFS as the primary end point performed to date. The trial included an economic analysis component based on standard methods for cost-effectiveness analysis in transplantation for leukemias and lymphoma. 11 While other studies have estimated the costs of URD transplantation, 12, 13 there has only been one prior analysis of the impact of TCD on costs and outcomes in URD recipients. 1 In that study, however, patients were not randomized, but were selected for either TCD or standard immunosuppressive therapy based on the attending physician recommendation and patient preferences after discussion of the risks and benefits of each method. 2 In concert with the study by Lee et al, we found a trend to lower cost of the index hospital admission for patients randomized to TCD relative to patients randomized to receive an unmodified transplant. Since room and pharmacy costs comprised nearly two-thirds of the total costs in our trial, the higher cost of the index hospitalization, with the longer LOS for patients receiving unmodified transplants, can be attributed almost entirely to the room and pharmacy costs.
As demonstrated in this study, there was no difference in costs between patients undergoing TCD vs unmodified transplants within each grade of acute GVHD. However, the severity of acute GVHD, as it occurs, adds significantly to the costs of transplant. Since there were fewer patients in the TCD arm who developed grades III and IV acute GVHD, there were less total costs associated with the initial hospital stay in the TCD arm. However, during the first 6 months following transplantation, there was a statistically insignificant increase in number of days of hospitalization relative to the unmodified group, which added to the costs of recipients of TCD transplants. This translated into an absence of overall difference in LOS or costs associated with TCD vs unmodified transplants during the combined index hospital admission and follow-up period. Savings on reduced cost for treating acute GVHD were likely offset by an increase in serious infections on the TCD arm. 14 When analyzed by duration of survival, there were no statistical differences between the TCD and unmodified arms. For recipients who lived less than 60 days, there was no difference in cost by treatment arm. Similarly, for patients who lived longer but died, the costs of the overall care were increased, but there were no statistical differences between the TCD and unmodified arms at any time period. However, surviving recipients of an unmodified transplant tended to have higher costs associated with that survival.
A trend to lower costs was observed when donors and recipients were more closely HLA matched (6/6 vs 5/6). During the course of this study, matching criteria required serologic testing at HLA-A, -B loci and high-resolution molecular match for DRB1. The effect on cost of transplantation based on the incidence of acute and chronic GVHD, with the use of more sensitive molecular based HLA typing, and requirements for matching at HLA-C, and -DQ, to obtain more closely matched donor-recipient pairs, remains to be determined.
None of the costs associated with preparing the donor marrow for infusion in the TCD arm were accounted for in this study. Two methods of TCD (elutriation with CD34 add back and T10B9 monoclonal antibody plus complement) were used during the conduct of this trial.
3 While TCD did decrease the incidence of significant acute GVHD, the mean difference in cost for those patients was not different between arms.
Treatment outcomes may be associated with transplant center volume. Previous studies of therapy such as management of pancreatic cancer have reported improved patient outcomes and lower costs for hospitals performing high volumes of a particular procedure relative to low-volume providers. 15 To explore the cost-volume relationship in the TCD trial, we expanded the multivariate regression as reported in Table 5 to explore the relationship between index hospital admission and total number of study patients enrolled. Results suggested that enrolling larger numbers of patients was associated with lower cost of the index admission. Note that this finding is only suggestive, since numbers of patients enrolled in the trial may not reflect the extent of institutional experience in bone marrow transplantation.
In summary, while TCD of the donor graft may reduce short-term costs associated with unrelated bone marrow transplantation, long-term complications leading to frequent hospitalizations and higher average number of hospital days in the first 6 months following transplantation appear to offset any savings seen with the initial transplant stay. More sensitive HLA typing methods for HLA-A and HLA-B, as well as matching at HLA-C and HLA-DQ to obtain more closely matched donor-recipient pairs, may be an alternative strategy to lowering costs with either TCD or unmodified transplants for individuals who may benefit from an unrelated hematopoietic stem cell transplant.
